Remdesivir Patent Expiration
Remdesivir is Used for treatment of COVID-19 in hospitalized and non-hospitalized adults and pediatric patients when concurrent use of other medications is not recommended. It was first introduced by Gilead Sciences Inc
Remdesivir Patents
Given below is the list of patents protecting Remdesivir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Veklury |
US11491169 (Pediatric) | Remdesivir treatment methods | Nov 28, 2041 | Gilead Sciences Inc |
| Veklury |
US11903953 (Pediatric) | Remdesivir treatment methods | Nov 28, 2041 | Gilead Sciences Inc |
| Veklury |
US11975012 (Pediatric) | Remdesivir treatment methods | Nov 28, 2041 | Gilead Sciences Inc |
| Veklury | US11491169 | Remdesivir treatment methods | May 28, 2041 | Gilead Sciences Inc |
| Veklury | US11903953 | Remdesivir treatment methods | May 28, 2041 | Gilead Sciences Inc |
| Veklury | US11975012 | Remdesivir treatment methods | May 28, 2041 | Gilead Sciences Inc |
| Veklury |
US10675296 (Pediatric) | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | Jan 10, 2039 | Gilead Sciences Inc |
| Veklury |
US11266681 (Pediatric) | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | Jan 10, 2039 | Gilead Sciences Inc |
| Veklury |
US11975017 (Pediatric) | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | Jan 10, 2039 | Gilead Sciences Inc |
| Veklury | US10675296 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | Jul 10, 2038 | Gilead Sciences Inc |
| Veklury | US11266681 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | Jul 10, 2038 | Gilead Sciences Inc |
| Veklury | US11975017 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | Jul 10, 2038 | Gilead Sciences Inc |
| Veklury |
US10695361 (Pediatric) | Methods for treating arenaviridae and coronaviridae virus infections | Mar 16, 2037 | Gilead Sciences Inc |
| Veklury |
US11007208 (Pediatric) | Methods for treating arenaviridae and coronaviridae virus infections | Mar 16, 2037 | Gilead Sciences Inc |
| Veklury |
US11382926 (Pediatric) | Methods for treating Arenaviridae and Coronaviridae virus infections | Mar 16, 2037 | Gilead Sciences Inc |
| Veklury | US10695361 | Methods for treating arenaviridae and coronaviridae virus infections | Sep 16, 2036 | Gilead Sciences Inc |
| Veklury | US11007208 | Methods for treating arenaviridae and coronaviridae virus infections | Sep 16, 2036 | Gilead Sciences Inc |
| Veklury | US11382926 | Methods for treating Arenaviridae and Coronaviridae virus infections | Sep 16, 2036 | Gilead Sciences Inc |
| Veklury |
US9724360 (Pediatric) | Methods for treating Filoviridae virus infections | Apr 29, 2036 | Gilead Sciences Inc |
| Veklury |
US9949994 (Pediatric) | Methods for treating Filoviridae virus infections | Apr 29, 2036 | Gilead Sciences Inc |
| Veklury | US9724360 | Methods for treating Filoviridae virus infections | Oct 29, 2035 | Gilead Sciences Inc |
| Veklury | US9949994 | Methods for treating Filoviridae virus infections | Oct 29, 2035 | Gilead Sciences Inc |
| Veklury |
US11492353 (Pediatric) | Methods and compounds for treating Paramyxoviridae virus infections | Jun 08, 2032 | Gilead Sciences Inc |
| Veklury |
US10065958 (Pediatric) | Methods and compounds for treating Paramyxoviridae virus infections | Mar 16, 2032 | Gilead Sciences Inc |
| Veklury | US11492353 | Methods and compounds for treating Paramyxoviridae virus infections | Dec 08, 2031 | Gilead Sciences Inc |
| Veklury | US10065958 | Methods and compounds for treating Paramyxoviridae virus infections | Sep 16, 2031 | Gilead Sciences Inc |
| Veklury |
US8008264 (Pediatric) | 1′-substituted carba-nucleoside analogs for antiviral treatment | Mar 06, 2030 | Gilead Sciences Inc |
| Veklury |
US8318682 (Pediatric) | 1′substituted carba-nucleoside analogs for antiviral treatment | Oct 22, 2029 | Gilead Sciences Inc |
| Veklury |
USRE46762 (Pediatric) | 1′-substituted carba-nucleoside analogs for antiviral treatment | Oct 22, 2029 | Gilead Sciences Inc |
| Veklury | US8008264 | 1′-substituted carba-nucleoside analogs for antiviral treatment | Sep 06, 2029 | Gilead Sciences Inc |
| Veklury | US8318682 | 1′substituted carba-nucleoside analogs for antiviral treatment | Apr 22, 2029 | Gilead Sciences Inc |
| Veklury | USRE46762 | 1′-substituted carba-nucleoside analogs for antiviral treatment | Apr 22, 2029 | Gilead Sciences Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Remdesivir's patents.
Latest Legal Activities on Remdesivir's Patents
Given below is the list recent legal activities going on the following patents of Remdesivir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 May, 2024 | US8318682 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9724360 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9949994 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8318682 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8008264 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US10065958 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US9724360 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US10065958 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US8008264 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US8318682 |
Remdesivir's Family Patents
